Burkitt’s Lymphoma
R-CODOX-M Therapy (Patients less than or equal to 65 years)
R-CODOX-M Therapy (Patients greater than 65 years)
R-IVAC Therapy Patients greater than 65 years
Indication
00404a
Treatment of patients with extensive Burkitt Lymphoma aged greater than 65 years.
R-IVAC Therapy Patients less than or equal to 65 years
Indication
00399a
Treatment of patients with extensive stage Burkitt Lymphoma aged less than or equal to 65 years.
Lymphoma Other (PCNSL, MCD, LLGL, MF, SS, CTCL)
riTUXimab, Methotrexate, Procarbazine and vinCRIStine (R-MPV) - 14 Days Induction Therapy
High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy
Indication
00666a
Consolidation chemotherapy for the treatment of patients with newly diagnosed primary CNS lymphoma (PCNSL)
High dose Methotrexate, high dose Cytarabine, riTUXimab and Thiotepa (MATRix)Therapy
Siltuximab Monotherapy
Indication
00277a
Treatment of adult patients with Multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative.
Mogamulizumab Therapy
Indication
00761a
As monotherapy for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy
Brentuximab vedotin Monotherapy
Indication
00234d
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
CHOEP Therapy - 21 days
SMILE Therapy (NK or T cell Lymphoma)
Indication
00407a
Newly diagnosed stage II - IV or relapsed/refractory extranodal natural killer/T-cell lymphoma